Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Glaukos Corporation

GKOSNYSEEQUITYCurrent

Notice of Proposed Sale

Filed Jul 16, 2026Accepted Jul 16, 2026, 12:18 PM EDTFiling CIK 1920061Accession 0001959173-26-005248
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
GLAUKOS Corp
Issuer CIK
0001192448
SEC file number
001-37463
Phone
949-367-9600
Person for whose account securities are to be sold
Thurman Alex R.
Relationships to issuer
Officer
Street
1 GLAUKOS WAY
City
ALISO VIEJO
State / country code
CA
Postal code
92656

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common10,0001,600,000.0058,733,91107/16/2026NYSEFidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name
Fidelity Brokerage Services LLC
Street
900 Salem Street
City
Smithfield
State / country code
RI
Postal code
02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common07/16/2026Stock Option ExerciseIssuer10,000N07/16/2026Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 3 reported rows
SellerSecuritySale dateAmount soldGross proceeds
Alex R. ThurmanCommon04/30/202610,0001,400,000.00
Alex R. ThurmanCommon07/06/202610,0001,500,000.00
Alex R. ThurmanCommon07/09/202610,0001,550,000.00

Seller — prior-sale row 1, entry 1

Name
Alex R. Thurman
Street
1 Glaukos Way
City
Aliso Viejo
State / country code
CA
Postal code
92656

Seller — prior-sale row 2, entry 1

Name
Alex R. Thurman
Street
1 Glaukos Way
City
Aliso Viejo
State / country code
CA
Postal code
92656

Seller — prior-sale row 3, entry 1

Name
Alex R. Thurman
Street
1 Glaukos Way
City
Aliso Viejo
State / country code
CA
Postal code
92656

Prior-sale reporting

Nothing to report for the preceding three months
N

Notice signature

Notice date
07/16/2026
Signed
/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Alex R. Thurman
Plan adoption dates
12/15/2025

Company context

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,

Current securities

Recent company filings

  1. Regulation FD DisclosureNov 6, 2026
  2. 10-Q filingOct 28, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureOct 28, 2026
  4. 144 filingSep 16, 2026
  5. 144 filingAug 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.